142 related articles for article (PubMed ID: 10202261)
1. Influence of age on the clinical presentation of prolactinomas in male patients.
Delgrange E; Maiter D; Donckier J; Tourniaire J
Gerontology; 1999; 45(3):160-4. PubMed ID: 10202261
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
[TBL] [Abstract][Full Text] [Related]
3. Hypopituitarism patterns among adult males with prolactinomas.
Peng J; Qiu M; Qi S; Li D; Peng Y
Clin Neurol Neurosurg; 2016 May; 144():112-8. PubMed ID: 27038873
[TBL] [Abstract][Full Text] [Related]
4. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
5. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
6. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
7. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
8. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.
Ribeiro RS; Abucham J
Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408
[TBL] [Abstract][Full Text] [Related]
9. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
11. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
13. [Clinical presentation, diagnostics and results of primary conservative treatment of large and giant prolactin-secreting pituitary adenomas].
Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Shkarubo AN; Fomichev DV; Faĭzullaev RB; Alekseev SN; Sidneva IuG; Tenedieva VD; Tropinskaia OF
Zh Vopr Neirokhir Im N N Burdenko; 2008; (4):36-8; discussion 39. PubMed ID: 19230480
[TBL] [Abstract][Full Text] [Related]
14. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinaemia in males: a heterogeneous disorder.
Walsh JP; Pullan PT
Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
[TBL] [Abstract][Full Text] [Related]
16. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
17. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.
Knoepfelmacher M; Gomes MC; Melo ME; Mendonca BB
Pituitary; 2004; 7(2):83-7. PubMed ID: 15761656
[TBL] [Abstract][Full Text] [Related]
18. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
19. Clinical practice. Prolactinomas.
Klibanski A
N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
[No Abstract] [Full Text] [Related]
20. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
